CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

Venetoclax plus anti-CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re-treatment with venetoclax plus anti-CD20 mAb and CD20-targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20-negative CLL in patients treated with fixed-duration venetoclax/obinutuzumab (Ven-O) or venetoclax/rituximab (Ven-R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T-cell controls was less than 0.5. Of 60 patients, (34 Ven-O, 26 Ven-R), 6 demonstrated pre-therapy CD20 negativity (1 treatment-naïve, 5 pre-treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post-therapy CD20 loss (4 Ven-O, 6 Ven-R). Notch receptor 1 (NOTCH1) variants were identified in 5/10 (50%) patients with CD20-negative MRD, compared to 3/18 (17%) with CD20-positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20-negative disease long after antibody exposure (follow-up 12-39 months). These results have potential implications for future treatment selection and efficacy.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-11-16
DOI
https://doi.org/10.1111/bjh.70948
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

Neil A. Came, Ing Soo Tiong, Kylie Baldwin, Kah Lok Chan et al.
2 links
British Journal of Haematology
Chronic Lymphocytic Leukemia Research
article

CD20 antigen loss post‐venetoclax/anti‐ CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

Neil A. Came, Ing Soo Tiong, Kylie Baldwin, Kah Lok Chan, Ashley Whitechurch, Sean Harrop, Sean J. McKeague, Tamasine Stewart, Philip A. Thompson, John Francis Seymour, Joshua M. L. Casan, Mary Ann Anderson, David Westerman, Divya Somasekharannair, Vuong Nguyen, Lei‐Shong Lau
article en

Abstract

Venetoclax plus anti-CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re-treatment with venetoclax plus anti-CD20 mAb and CD20-targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20-negative CLL in patients treated with fixed-duration venetoclax/obinutuzumab (Ven-O) or venetoclax/rituximab (Ven-R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T-cell controls was less than 0.5. Of 60 patients, (34 Ven-O, 26 Ven-R), 6 demonstrated pre-therapy CD20 negativity (1 treatment-naïve, 5 pre-treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post-therapy CD20 loss (4 Ven-O, 6 Ven-R). Notch receptor 1 (NOTCH1) variants were identified in 5/10 (50%) patients with CD20-negative MRD, compared to 3/18 (17%) with CD20-positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20-negative disease long after antibody exposure (follow-up 12-39 months). These results have potential implications for future treatment selection and efficacy.

British Journal of Haematology
The Royal Melbourne Hospital (AU), The University of Melbourne (AU), La Trobe University (AU), Royal Brisbane and Women's Hospital (AU), Peter MacCallum Cancer Centre (AU)
Good health and well-being
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon